REG - Intnl. Biotechnology - Restatement of Net Asset Value(s)

International Biotechnology TrustAnnouncement

10/02/2026 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260210:nRSJ4572Sa&default-theme=true

RNS Number : 4572S  Intl. Biotechnology Trust PLC  10 February 2026

10 February 2026

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

 Restatement of Net Asset Value(s)

 

The Board of International Biotechnology Trust plc (the "Company") announces
that, due to an administrative error relating to the non-accrual of the
Company's most recent interim dividend, the Company's unaudited cum income net
asset value ("NAV") per share has been restated for the following dates, as
follows:

 

 Date        Published Cum Income NAV per Share  Revised Cum Income NAV per Share
 29/12/2025  1021.50                             1005.87
 30/12/2025  1016.30                             1000.69
 31/12/2025  1024.00                             1008.35
 02/01/2026  1013.20                             997.59
 05/01/2026  998.07                              982.44
 06/01/2026  1004.10                             988.51
 07/01/2026  1035.70                             1020.10
 08/01/2026  1025.30                             1009.67
 09/01/2026  1032.20                             1016.53
 12/01/2026  1010.90                             995.29
 13/01/2026  1007.40                             991.72
 14/01/2026  1031.00                             1015.36
 15/01/2026  1021.10                             1005.51
 16/01/2026  1013.60                             997.96
 19/01/2026  1009.70                             994.04

 

As a result, the Company's service providers have implemented corrective
measures and enhanced their procedures.

 

Enquiries:

Natalia de Sousa

Schroder Investment Management Limited

Tel: 020 7658 6000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRSFFFESEMSESE



            Copyright 2019 Regulatory News Service, all rights reserved